Jim Cramer on AstraZeneca: “On Track to Hit the Ambitious Long-Term Financial Targets”

AstraZeneca PLC (NYSE:AZN) was among the stocks Jim Cramer discussed on Mad Money, along with the recent sell-off in the market. Cramer highlighted the company’s stock transfer to the NYSE, as he remarked:

This morning, the pharmaceutical company, AstraZeneca, rang the opening bell to celebrate their transfer to the New York Stock Exchange. It’s the largest transfer in the history of the 234-year-old institution. The British pharma stock has rallied 30% over the past 12 months. It’s been a good one, and it’s very much on track to hit the ambitious long-term financial targets they rolled out in 2024. That’s largely thanks to the company’s booming oncology business.

A stock market graph. Photo by Alesia Kozik on Pexels

AstraZeneca PLC (NYSE:AZN) manufactures prescription medicines for oncology, cardiovascular, respiratory, and rare diseases. During the January 30 episode, a caller noted that they were considering selling their position in the company’s stock for a profit and buying ABBV. Cramer replied:

I like AstraZeneca very much. And that cancer franchise turned out to be a lot stronger than I thought. I think you should hold onto that. AbbVie reports this week. I expect a very good quarter. I like the dividend, but I think AstraZeneca has got a better portfolio at this very moment.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.